ALK and rhabdomyosarcoma: For example, while alterations in ALK tend to be gene fusions in STS, ALK alteration in rhabdomyosarcoma is mainly amplification, thus the investigated ALK inhibitor crizotinib is not effective for rhabdomyosarcoma.33